Candidaskin test reagent as a novel adjuvant for a human papillomavirus peptide-based therapeutic vaccine

A vaccine adjuvant that can effectively promote cell-mediated immunity is currently not available. Because of the ability of aCandidaskin test reagent injection to induce common wart regression, our group is using it as a novel adjuvant in a clinical trial of a peptide-based human papillomavirus the...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2013-12, Vol.31 (49), p.5806
Main Authors: Wang, Xuelian, Coleman, Hannah N, Nagarajan, Uma, Spencer, Horace J, Nakagawa, Mayumi
Format: Article
Language:English
Subjects:
Cell growth
Cervical cancer
Clinical trials
Cytokines
Human papillomavirus
Infections
Lymphocytes
Pattern recognition
Peptides
Vaccines
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 49
container_start_page 5806
container_title Vaccine
container_volume 31
creator Wang, Xuelian
Coleman, Hannah N
Nagarajan, Uma
Spencer, Horace J
Nakagawa, Mayumi
description A vaccine adjuvant that can effectively promote cell-mediated immunity is currently not available. Because of the ability of aCandidaskin test reagent injection to induce common wart regression, our group is using it as a novel adjuvant in a clinical trial of a peptide-based human papillomavirus therapeutic vaccine. The goal of this current study was to investigate the mechanisms of howCandidaenhances the vaccine immune responses. Maturation effects on Langerhans cells, capacity to proliferate T-cells, expression of cytokines and pattern recognition receptors by Langerhans cells, and ability to induce Th1, Th2, and Th17 responses were investigated in healthy subjects. The vaccine, human papillomavirus peptides withCandida, demonstrated partial maturation effects on Langerhans cells indicated by significantly up-regulated CD40 (p=0.00007) and CD80 (p
doi_str_mv 10.1016/j.vaccine.2013.10.014
format article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_1552881254</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3401028901</sourcerecordid><originalsourceid>FETCH-proquest_journals_15528812543</originalsourceid><addsrcrecordid>eNqNjk1OwzAQhS1EJQLlCEgjsU7wOHEJ6wrEAViwq4Z4Sh1S2_gn58eLHoDVk773Se8J8YCyQ4m7p7lbaZqs405J7CvrJA5XosHxuW-VxvFaNFLthnZA-XkjblOapZS6x5dG2D05Yw2lH-sgc8oQmb7ZZaAEBM6vvACZuaxU2dHHCk_lTA4CBbss_kyrjSVB4JCt4faLEhvIJ44UuGQ7weXcVmyOtCS-v-SdeHx7_di_tyH631KXD7Mv0dXqgFqrcUSlh_5_1h9qZFGU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1552881254</pqid></control><display><type>article</type><title>Candidaskin test reagent as a novel adjuvant for a human papillomavirus peptide-based therapeutic vaccine</title><source>ScienceDirect Journals</source><creator>Wang, Xuelian ; Coleman, Hannah N ; Nagarajan, Uma ; Spencer, Horace J ; Nakagawa, Mayumi</creator><creatorcontrib>Wang, Xuelian ; Coleman, Hannah N ; Nagarajan, Uma ; Spencer, Horace J ; Nakagawa, Mayumi</creatorcontrib><description>A vaccine adjuvant that can effectively promote cell-mediated immunity is currently not available. Because of the ability of aCandidaskin test reagent injection to induce common wart regression, our group is using it as a novel adjuvant in a clinical trial of a peptide-based human papillomavirus therapeutic vaccine. The goal of this current study was to investigate the mechanisms of howCandidaenhances the vaccine immune responses. Maturation effects on Langerhans cells, capacity to proliferate T-cells, expression of cytokines and pattern recognition receptors by Langerhans cells, and ability to induce Th1, Th2, and Th17 responses were investigated in healthy subjects. The vaccine, human papillomavirus peptides withCandida, demonstrated partial maturation effects on Langerhans cells indicated by significantly up-regulated CD40 (p=0.00007) and CD80 (p&lt;0.00001) levels, and showed T-cell proliferative capacity (p&lt;0.00001) when presented by Langerhans cells in vitro. Interestingly, the maturation effects were due to the peptides whileCandidawas responsible for the T-cell proliferation. The cytokine profile (IL-1β, IL-6, IL-8, IL-10, IL-12p40, IL-23Ap19, IFN-γ and TNF-[alpha]) of Langerhans cells treated with the vaccine orCandidaalone showed that IL-12p40 mRNA was most frequently induced, and IL-12p70 protein was detected in the supernatants. The presence of pattern recognition receptors known to associate withCandida albicans(DC-SIGN, dectin-1, dectin-2, galectin-3, mincle, mannose receptor, Toll-like receptors-1, 2, 4, 6 and 9) were demonstrated in all subjects. On the other hand, the induction of Th1 response demonstrated by IFN-γ secretion by CD4 cells stimulated with the vaccine orCandidapulsed Langerhans cells was demonstrated only in one subject. In summary, the Langerhans cell maturation effects of the vaccine were due to the peptides while the T-cell proliferative capacity was derived fromCandida, and the most frequently induced cytokine was IL-12.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2013.10.014</identifier><language>eng</language><publisher>Kidlington: Elsevier Limited</publisher><subject>Cell growth ; Cervical cancer ; Clinical trials ; Cytokines ; Human papillomavirus ; Infections ; Lymphocytes ; Pattern recognition ; Peptides ; Vaccines</subject><ispartof>Vaccine, 2013-12, Vol.31 (49), p.5806</ispartof><rights>Copyright Elsevier Limited Dec 2, 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Wang, Xuelian</creatorcontrib><creatorcontrib>Coleman, Hannah N</creatorcontrib><creatorcontrib>Nagarajan, Uma</creatorcontrib><creatorcontrib>Spencer, Horace J</creatorcontrib><creatorcontrib>Nakagawa, Mayumi</creatorcontrib><title>Candidaskin test reagent as a novel adjuvant for a human papillomavirus peptide-based therapeutic vaccine</title><title>Vaccine</title><description>A vaccine adjuvant that can effectively promote cell-mediated immunity is currently not available. Because of the ability of aCandidaskin test reagent injection to induce common wart regression, our group is using it as a novel adjuvant in a clinical trial of a peptide-based human papillomavirus therapeutic vaccine. The goal of this current study was to investigate the mechanisms of howCandidaenhances the vaccine immune responses. Maturation effects on Langerhans cells, capacity to proliferate T-cells, expression of cytokines and pattern recognition receptors by Langerhans cells, and ability to induce Th1, Th2, and Th17 responses were investigated in healthy subjects. The vaccine, human papillomavirus peptides withCandida, demonstrated partial maturation effects on Langerhans cells indicated by significantly up-regulated CD40 (p=0.00007) and CD80 (p&lt;0.00001) levels, and showed T-cell proliferative capacity (p&lt;0.00001) when presented by Langerhans cells in vitro. Interestingly, the maturation effects were due to the peptides whileCandidawas responsible for the T-cell proliferation. The cytokine profile (IL-1β, IL-6, IL-8, IL-10, IL-12p40, IL-23Ap19, IFN-γ and TNF-[alpha]) of Langerhans cells treated with the vaccine orCandidaalone showed that IL-12p40 mRNA was most frequently induced, and IL-12p70 protein was detected in the supernatants. The presence of pattern recognition receptors known to associate withCandida albicans(DC-SIGN, dectin-1, dectin-2, galectin-3, mincle, mannose receptor, Toll-like receptors-1, 2, 4, 6 and 9) were demonstrated in all subjects. On the other hand, the induction of Th1 response demonstrated by IFN-γ secretion by CD4 cells stimulated with the vaccine orCandidapulsed Langerhans cells was demonstrated only in one subject. In summary, the Langerhans cell maturation effects of the vaccine were due to the peptides while the T-cell proliferative capacity was derived fromCandida, and the most frequently induced cytokine was IL-12.</description><subject>Cell growth</subject><subject>Cervical cancer</subject><subject>Clinical trials</subject><subject>Cytokines</subject><subject>Human papillomavirus</subject><subject>Infections</subject><subject>Lymphocytes</subject><subject>Pattern recognition</subject><subject>Peptides</subject><subject>Vaccines</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNqNjk1OwzAQhS1EJQLlCEgjsU7wOHEJ6wrEAViwq4Z4Sh1S2_gn58eLHoDVk773Se8J8YCyQ4m7p7lbaZqs405J7CvrJA5XosHxuW-VxvFaNFLthnZA-XkjblOapZS6x5dG2D05Yw2lH-sgc8oQmb7ZZaAEBM6vvACZuaxU2dHHCk_lTA4CBbss_kyrjSVB4JCt4faLEhvIJ44UuGQ7weXcVmyOtCS-v-SdeHx7_di_tyH631KXD7Mv0dXqgFqrcUSlh_5_1h9qZFGU</recordid><startdate>20131202</startdate><enddate>20131202</enddate><creator>Wang, Xuelian</creator><creator>Coleman, Hannah N</creator><creator>Nagarajan, Uma</creator><creator>Spencer, Horace J</creator><creator>Nakagawa, Mayumi</creator><general>Elsevier Limited</general><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope></search><sort><creationdate>20131202</creationdate><title>Candidaskin test reagent as a novel adjuvant for a human papillomavirus peptide-based therapeutic vaccine</title><author>Wang, Xuelian ; Coleman, Hannah N ; Nagarajan, Uma ; Spencer, Horace J ; Nakagawa, Mayumi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_15528812543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Cell growth</topic><topic>Cervical cancer</topic><topic>Clinical trials</topic><topic>Cytokines</topic><topic>Human papillomavirus</topic><topic>Infections</topic><topic>Lymphocytes</topic><topic>Pattern recognition</topic><topic>Peptides</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Xuelian</creatorcontrib><creatorcontrib>Coleman, Hannah N</creatorcontrib><creatorcontrib>Nagarajan, Uma</creatorcontrib><creatorcontrib>Spencer, Horace J</creatorcontrib><creatorcontrib>Nakagawa, Mayumi</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>PML(ProQuest Medical Library)</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Xuelian</au><au>Coleman, Hannah N</au><au>Nagarajan, Uma</au><au>Spencer, Horace J</au><au>Nakagawa, Mayumi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Candidaskin test reagent as a novel adjuvant for a human papillomavirus peptide-based therapeutic vaccine</atitle><jtitle>Vaccine</jtitle><date>2013-12-02</date><risdate>2013</risdate><volume>31</volume><issue>49</issue><spage>5806</spage><pages>5806-</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>A vaccine adjuvant that can effectively promote cell-mediated immunity is currently not available. Because of the ability of aCandidaskin test reagent injection to induce common wart regression, our group is using it as a novel adjuvant in a clinical trial of a peptide-based human papillomavirus therapeutic vaccine. The goal of this current study was to investigate the mechanisms of howCandidaenhances the vaccine immune responses. Maturation effects on Langerhans cells, capacity to proliferate T-cells, expression of cytokines and pattern recognition receptors by Langerhans cells, and ability to induce Th1, Th2, and Th17 responses were investigated in healthy subjects. The vaccine, human papillomavirus peptides withCandida, demonstrated partial maturation effects on Langerhans cells indicated by significantly up-regulated CD40 (p=0.00007) and CD80 (p&lt;0.00001) levels, and showed T-cell proliferative capacity (p&lt;0.00001) when presented by Langerhans cells in vitro. Interestingly, the maturation effects were due to the peptides whileCandidawas responsible for the T-cell proliferation. The cytokine profile (IL-1β, IL-6, IL-8, IL-10, IL-12p40, IL-23Ap19, IFN-γ and TNF-[alpha]) of Langerhans cells treated with the vaccine orCandidaalone showed that IL-12p40 mRNA was most frequently induced, and IL-12p70 protein was detected in the supernatants. The presence of pattern recognition receptors known to associate withCandida albicans(DC-SIGN, dectin-1, dectin-2, galectin-3, mincle, mannose receptor, Toll-like receptors-1, 2, 4, 6 and 9) were demonstrated in all subjects. On the other hand, the induction of Th1 response demonstrated by IFN-γ secretion by CD4 cells stimulated with the vaccine orCandidapulsed Langerhans cells was demonstrated only in one subject. In summary, the Langerhans cell maturation effects of the vaccine were due to the peptides while the T-cell proliferative capacity was derived fromCandida, and the most frequently induced cytokine was IL-12.</abstract><cop>Kidlington</cop><pub>Elsevier Limited</pub><doi>10.1016/j.vaccine.2013.10.014</doi></addata></record>
fulltext fulltext
identifier ISSN: 0264-410X
ispartof Vaccine, 2013-12, Vol.31 (49), p.5806
issn 0264-410X
1873-2518
language eng
recordid cdi_proquest_journals_1552881254
source ScienceDirect Journals
subjects Cell growth
Cervical cancer
Clinical trials
Cytokines
Human papillomavirus
Infections
Lymphocytes
Pattern recognition
Peptides
Vaccines
title Candidaskin test reagent as a novel adjuvant for a human papillomavirus peptide-based therapeutic vaccine
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T23%3A50%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Candidaskin%20test%20reagent%20as%20a%20novel%20adjuvant%20for%20a%20human%20papillomavirus%20peptide-based%20therapeutic%20vaccine&rft.jtitle=Vaccine&rft.au=Wang,%20Xuelian&rft.date=2013-12-02&rft.volume=31&rft.issue=49&rft.spage=5806&rft.pages=5806-&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2013.10.014&rft_dat=%3Cproquest%3E3401028901%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-proquest_journals_15528812543%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1552881254&rft_id=info:pmid/&rfr_iscdi=true